clinical trial · NCT07473128
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Pharmacosmos A/S·phase3·not yet recruiting·n = 120
Limited Stage Small Cell Lung CancerTrilaciclibSaline (0.9% NaCl)
brief summary
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
started
Mar 31, 2026
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Mar 16, 2026
official title
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol